ArticleMikrochimica acta2025
Integrated microfluidic cartridge for rapid and colorimetric detection of Mycoplasma pneumoniae.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Mycoplasma pneumoniae is a major cause of community-acquired pneumonia, yet its diagnosis remains challenging due to overlapping symptoms with other respiratory pathogens. In this study, an integrated microfluidic cartridge platform has been developed that combines three synergistic advancements: a chemical lysis reagent (GuHCl/EDTA) enabling direct genomic DNA release from M. pneumoniae collected by nasal swabs within 2 min without extraction steps, a novel dual-dye system (hydroxy naphthol blue/SYBR Green I) that leverages complementary fluorescence transitions from red to green for enhanced visual discrimination of loop-mediated isothermal amplification (LAMP) results, and a smartphone-based RGB quantification algorithm to standardize interpretation by analyzing colorimetric changes. The microfluidic cartridge integrates lysis, amplification, and detection into a closed workflow, achieving a sample-to-answer time of 40 min with a detection limit of 1 copy/μL. Clinical validation using 25 nasal swab samples demonstrated 95% sensitivity (19/20) and 100% specificity (5/5) compared with serological tests. This platform offers a rapid, cost-effective, and user-friendly solution for point-of-care diagnosis of M. pneumoniae, particularly in resource-limited settings.
Indexed as
Identifiers
40767967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.